Shares of Bristol Myers Squibb Co. BMY rose 3.67% to $57.88 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.08% to 43,461.21 and the S&P 500 Index SPX falling 0.50% to 5,983.25. This was the stock's fifth consecutive day of gains.

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make decisions quickly and to be accountable for those decisions."

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The trades have taken place between February 18, 2025 and February 21, 2025. • JPMorgan Chase (NYSE:JPM) disclosed a series of transactions this week.

For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with Celgene in one of the biggest acquisitions in pharmaceutical history, the company’s treasury team needed to regroup.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $60.0 for Bristol-Myers Squibb, spanning the last three months.